An interventional study of High-Intensity Laser Therapy in Eosinophilic Fasciitis, sponsored by Ahram Canadian University. Recruiting at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2023-06-23.
Sponsored by Ahram Canadian University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Eosinophilic fasciitis (EF) is a rare musculoskeletal disorder characterized by inflammation and thickening of the fascia, leading to pain, stiffness, and functional impairment. Conventional treatment options include immunosuppressive medications, corticosteroids, and physical therapy. This case report will describe use of high-intensity laser therapy (HILT) using the Mectronic Exand MY high-intensity laser system in a patient with EF, highlighting its potential as an alternative or adjunct treatment option.
Ahram Canadian University is the lead sponsor of 71 studies on the registry; 41 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: High-Intensity Laser Therapy
The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters: Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session
Pain intensity via Numeric pain rating scale
Time frame: Changes in pain intensity at baseline and 4 weeks
Functional outcomes via Disabilities of the Arm, Shoulder and Hand questionnaire (DASH)
Time frame: Changes in DASH at baseline and 4 weeks
Quality of life via Short Form-36 Health Survey
Time frame: Changes in Short Form-36 Health Survey at baseline and 4 weeks
Adverse event
adverse events are recorded by the patient and therapist
Time frame: 4 Weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2023; primary completion for Jul 2023, 1 month later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eosinophilic Fasciitis
Ahram Canadian University